… -agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed
on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the …

… in efficacy between gefitinib, erlotinib, or … erlotinib and gefitinib (NCT01955421); a phase
3 trial comparing dacomitinib (a second-generation tyrosine kinase inhibitor) versus gefitinib (…

… LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a … ),
as second-line treatment for patients with advanced squamous cell carcinoma of the lung. …

… It is known that 50%‒60% of patients treated with erlotinib or gefitinib develop T790M-…
compared gefitinib with erlotinib and found no difference in efficacy and safety [26], LUX-Lung 7 is …

… to reversible TKIs such as gefitinib and erlotinib develops in all … M, that renders gefitinib and
erlotinib ineffective inhibitors of EGFR/… to gefitinib and erlotinib in T790 M models in vivo [14]. …

… Findings from a meta-analysis of 13 randomised studies examining first-line gefitinib or
erlotinib (monotherapy or combined with chemotherapy) compared with chemotherapy or …

… vs gefitinib in patients with treatment-naïve epidermal growth factor receptor mutation-positive
non-small cell lung … afatinib/gefitinib beyond initial radiological progression in LUX-Lung 7. …

… Nowadays we have different drugs (afatinib, erlotinib and gefitinib) available for patients …
Waiting for the result of LUX-Lung 7 trial, a head-to-head study comparing afatinib with gefitinib, …

… benefit is not produced by gefitinib or erlotinib. For example, if … LUX-Lung 3 and LUX-Lung
6 trials was larger than the number of patients in trials that investigated gefitinib or erlotinib …

… Here, we describe the activity of afatinib in patients with uncommon EGFR mutations in the
LUX-Lung clinical trials programme, with data from the non-randomised phase 2 LUX-Lung 2 …